Gossamer Bio, Inc. Reports Results of 2026 Annual Shareholder Meeting
San Diego, CA – June 4, 2026 – Gossamer Bio, Inc. (NASDAQ: GOSS), a clinical-stage biopharmaceutical company, has released the results of its 2026 Annual Meeting of Stockholders, which included the election of directors, the ratification of its independent public accounting firm, and an advisory vote on executive compensation.
Key Points from the 2026 Annual Meeting
- Re-Election of Directors: Two Class II directors were re-elected to serve three-year terms, expiring at the 2029 annual meeting:
- Fahreem Hasnain: Received 92,301,637 votes “For”, 26,667,876 votes “Withheld”, and 45,450,098 “Broker Non-Votes”.
- Another Class II Director: Received 29,993,533 votes “For”, 45,450,098 votes “Withheld”, and the same “Broker Non-Votes” (details suggest this is a second director, though the name is not explicit in the data).
Shareholder takeaway: The re-election of directors, especially with a significant number of withheld votes, may indicate some shareholder dissatisfaction or call for change at the board level. However, both directors were re-elected with a majority of votes.
- Ratification of Independent Registered Public Accounting Firm:
- Ernst & Young LLP was re-appointed as the company’s independent auditor for the fiscal year ending December 31, 2026, with overwhelming support: 163,185,993 votes “For”, 1,192,448 votes “Against”, 41,170 “Abstain”, and zero “Broker Non-Votes”.
Shareholder takeaway: Routine ratification with very strong support, suggesting confidence in the company’s financial oversight.
- Advisory Vote on Executive Compensation (“Say-on-Pay”):
- The compensation of Gossamer Bio’s named executive officers was approved on an advisory basis, with 111,286,550 votes “For”, 7,545,502 votes “Against”, 137,461 “Abstain”, and 45,450,098 “Broker Non-Votes”.
Shareholder takeaway: While the majority supported executive compensation, the presence of over 7.5 million votes against and over 45 million broker non-votes may indicate evolving shareholder perspectives on pay practices.
Financial and Shareholder Information
- Company Overview: Gossamer Bio, Inc. is incorporated in Delaware, with its principal executive offices located at 3115 Merryfield Row, Suite 120, San Diego, CA 92121. The company trades on the Nasdaq Global Select Market under the symbol “GOSS”.
- Emerging Growth Company Status: Gossamer Bio is no longer considered an “Emerging Growth Company” under relevant SEC rules.
- No Amendments or Special Communications: The filing was not an amendment and did not include any written or pre-commencement communications under SEC rules.
Potential Share Price Implications & Shareholder Considerations
- Board Confidence vs. Shareholder Activism: The re-election of directors suggests stability at the board level, but the sizable “withheld” votes may point to growing shareholder scrutiny. If activist investors or major shareholders are dissatisfied, this could lead to governance changes in the future, potentially impacting share price.
- Executive Compensation Sentiment: Although the advisory vote passed, more than 7.5 million votes were cast against executive compensation. This level of dissent, combined with a large broker non-vote, signals that executive pay could become a topic of increased focus among shareholders and proxy advisers in the coming year.
- Auditor Ratification: The overwhelming support for Ernst & Young LLP as the company’s independent auditor reassures investors about the integrity of Gossamer Bio’s financial practices.
- No Material Non-Public Disclosures: This report does not reference any new business developments, product news, mergers, acquisitions, or other material events that would be considered immediately price-sensitive.
Summary Table of Voting Results
| Proposal | For | Against/Withheld | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Director: Fahreem Hasnain | 92,301,637 | 26,667,876 | – | 45,450,098 |
| Director: [Second Class II Director] | 29,993,533 | 45,450,098 | – | 45,450,098 |
| Ratification of Auditor | 163,185,993 | 1,192,448 | 41,170 | – |
| Executive Compensation (Say-on-Pay) | 111,286,550 | 7,545,502 | 137,461 | 45,450,098 |
Conclusion
The 2026 Annual Meeting for Gossamer Bio, Inc. did not reveal any new, material company developments or unexpected events that would be considered immediately price-sensitive. The results reflect routine annual meeting business, with a few areas of shareholder dissent—particularly around director re-elections and executive compensation—that investors should monitor for future governance or compensation policy changes. No new strategic initiatives or significant business changes were announced.
Disclaimer: This article is based on the official SEC Form 8-K and related filings for Gossamer Bio, Inc. as of June 4, 2026. It is intended solely for informational purposes and does not constitute investment advice. Investors should conduct their own due diligence or consult a financial advisor before making investment decisions.
